You are here: Industry Insights > radionuclide

News List

ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors B3Cnewswire
December 03, 2021
ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company and Navigo Proteins GmbH, a premier protein engineering company developing optimized scaffold protein-based affinity ligands...
Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody prnasia
June 02, 2021
Transcenta Holding Limited announced completion of first patient dosing in PET-CT imaging study of radionuclide-labeled CLDN18.2 antibody.
Novel radionuclide therapy found to be more effective in NET patients europeanpharmaceuticalreview
March 24, 2021
The study shows modifying the standard of care for late-stage neuroendocrine tumours (NETs) with Evans blue dye makes the treatment more effective and potentially less toxic.
ITM, DCB sign agreement for Targeted Radionuclide Therapy biospectrumasia
September 03, 2019
The agreement sets out terms concerning the local development, registration and subsequent commercialization by DCB of ITM’s proprietary brand Solucin® for Targeted Radionuclide Therapy (TRT).
NICE backs radionuclide therapy for some neuroendocrine tumours pharmatimes
July 23, 2018
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).